The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa

Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age12-18
SponsorSheba Medical Center

About this trial

The aim of this study is to determine whether 9-cis-beta Caroten rich D. Brdawiil extract is effective in the treatment of retinitis pigmentosa in adolescent patients.

Eligibility criteria

Qualifiers

Written informed consent to participate in the study.

Adolescent 12-18 years old.

Electroretinogram (ERG) responses compatible with the diagnosis of Retinitis Pigmentosa

Disqualifiers

Currently a smoker

Current use of vitamin A/ β-carotene supplements

Active arterial disease within 3 months prior to enrolment in the study, e.g. unstable angina, myocardial infarction, transient ischemic attack, stroke, coronary artery bypass graft surgery

History of malignancy, excepting basal or squamous cell skin carcinoma

Trial design

Treatments tested in this trial

  • Alga Dunaliella Bardawil powder
  • Placebo:Starch

Treatment groups

30 Participants
are divided into 2 treatment groups

Sponsors and collaborators